Eupafolin Suppresses Esophagus Cancer Growth by Targeting T-LAK Cell-Originated Protein Kinase

doi:10.3389/fphar.2019.01248

科研成果详情

题名	Eupafolin Suppresses Esophagus Cancer Growth by Targeting T-LAK Cell-Originated Protein Kinase
作者	Fan, Xiaoming 1; Tao, Junyan 2; Fredimoses, Mangaladoss 3; Wu, Junzi 4; Jiang, Zhihui 1; Zhang, Kunpeng 1; Zhang, Xiaoying 1,5; Li, Shude 6,7
发表日期	2019-10-22
发表期刊	FRONTIERS IN PHARMACOLOGY 影响因子和分区
语种	英语
原始文献类型	Article
关键词	eupafolin esophagus cancer TOPK inhibitor Ay Tsao
其他关键词	DESIGN
摘要	Eupafolin is the main bioactive component extracted from the traditional Chinese medicine Ay Tsao (Artemisia vulgaris L.), and its anti-tumor activity has had been studied in previous researches. T-LAK cell-originated protein kinase (TOPK) belongs to serine/threonine protein kinase and is highly expressed in several cancer cells and tissues, such as colon cancer, lung cancer, esophagus cancer, and so on. Therefore, it was recognized as an important target for treating tumors. Nowadays, we found that eupafolin suppressed TOPK activities at the first time in vitro and in vivo. The cells study indicated that eupafolin suppressed TOPK activities in JB6 Cl41 and KYSE450 cells. Furthermore, knockdown of TOPK in KYSE450 cells decreased their sensitivities to eupafolin. The animal study showed that the injection of eupafolin in patient-derived xenograft (PDX) mouse effectively suppressed tumor growth. Histone H3 and Ki67 were reduced, and cleaved caspase 3 was increased in tumor tissues after eupafolin treatment. To sum up, eupafolin as an TOPK inhibitor can suppress growth of esophagus cancer in vitro and in vivo. The TOPK downstream signaling molecule histone H3 in tumor tissues was also reduced after eupafolin treatment. In short, eupafolin can suppress growth of esophagus cancer cells as an TOPK inhibitor both in vitro and in vivo.
资助项目	PhD start-up fund of Anyang Institute of Technology [40075815]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81360128]; Scientific and Technological Development Project of Yunnan Province [2018FE001-162,2017FE467]; Education Department Fund of Yunnan Province [2017YJS076]
出版者	FRONTIERS MEDIA SA
出版地	LAUSANNE
ISSN	1663-9812
卷号	10 页码:1248
DOI	10.3389/fphar.2019.01248
页数	11
WOS类目	Pharmacology & Pharmacy
WOS研究方向	Pharmacology & Pharmacy
WOS记录号	WOS:000495385400001
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	31708778
PMC记录号	PMC6822407
SCOPUSEID	2-s2.0-85074762392
通讯作者地址	[Li, Shude]Department of Biochemistry and Molecular Biology,School of Basic Medicine,Kunming Medical University,Kunming,China
Scopus学科分类	Pharmacology;Pharmacology (medical)
引用统计	被引频次：13[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/19556
专题	公共卫生学院_环境安全与健康风险评估研究院
通讯作者	Li, Shude
作者单位	1.Henan Joint International Research Laboratory of Veterinary Biologics Research and Application,Anyang Institute of Technology,Anyang,China; 2.Institute of Environmental Safety and Human Health,Wenzhou Medical University,Wenzhou,China; 3.Laboratory of Natural Product Extraction,China-US (Henan) Hormel Cancer Institute,Zhengzhou,China; 4.College of Basic Medical,Yunnan University of Chinese Medicine,Kunming,China; 5.College of Veterinary Medicine,Northwest A and F University,Yangling,China; 6.Department of Biochemistry and Molecular Biology,School of Basic Medicine,Kunming Medical University,Kunming,China; 7.Yunnan Province Key Laboratory for Nutrition and Food Safety in Universities,Kunming, Yunnan,China
推荐引用方式 GB/T 7714	Fan, Xiaoming,Tao, Junyan,Fredimoses, Mangaladoss,et al. Eupafolin Suppresses Esophagus Cancer Growth by Targeting T-LAK Cell-Originated Protein Kinase[J]. FRONTIERS IN PHARMACOLOGY,2019,10:1248.
APA	Fan, Xiaoming., Tao, Junyan., Fredimoses, Mangaladoss., Wu, Junzi., Jiang, Zhihui., ... & Li, Shude. (2019). Eupafolin Suppresses Esophagus Cancer Growth by Targeting T-LAK Cell-Originated Protein Kinase. FRONTIERS IN PHARMACOLOGY, 10, 1248.
MLA	Fan, Xiaoming,et al."Eupafolin Suppresses Esophagus Cancer Growth by Targeting T-LAK Cell-Originated Protein Kinase".FRONTIERS IN PHARMACOLOGY 10(2019):1248.